Company and Stock Identity

How Odin Vision Connects to the Public Market

Company structure
Olympus cloud AI endoscopy business
Market access
Public parent: Olympus Corporation, Tokyo Stock Exchange.
Stock name
Olympus Corporation
Research focus
Olympus sells the endoscopes as well as the software, so ask whether CADDIE is being bought on its own merits or bundled into an equipment deal. Three clearances sit under the applicant name Odin Medical Limited in this site's FDA records, the newest dated 12 September 2026. Odin Vision publishes no news page of its own and points to the Olympus newsroom instead, so Olympus releases are the only first-hand trail for this product line.

Olympus announced on 5 June 2023 that it had acquired Odin Vision, which it describes as a London-based cloud AI endoscopy company, and Odin Vision's own site states that it is now part of Olympus. Olympus says on its investor pages that its shares are listed on the Tokyo Stock Exchange. The securities code was not shown on the Olympus pages read on 2026-10-10, so no ticker is recorded here.

A current price is not available in the automated United States market snapshot. Use the named exchange or the company investor-relations page for current trading data.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

No dated update is in the editorial file yet. Use the verified company sources below and check the profile verification date before relying on an older announcement.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: The careers site listed an AI product manager role and a 13-month fixed-term AI medical devices specialist role, and says the company has about 60 employees and was founded in 2019.

Qualification signal: This is a cloud product inside a device company, so the hard hire is someone who can carry a regulated medical device through its paperwork while still shipping cloud software on a normal release cycle.

Check current roles at Odin Vision. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Radiology leadership, pathology leadership, clinical informatics, imaging IT, patient safety, and procurement
Primary use case
Triage studies, flag findings, support image interpretation, and coordinate time-sensitive care
Typical deployment
Usually integrated with PACS, RIS, worklists, or digital pathology systems and monitored inside the clinical workflow

Evidence questions

  • Was the tool tested prospectively and independently on comparable equipment and patients?
  • What are sensitivity, specificity, false positive workload, and time-to-action effects?
  • How does performance vary by site, scanner, demographic subgroup, and disease prevalence?

Regulatory and workflow questions

  • Which FDA authorization covers the exact product version, modality, and intended use?
  • Who retains final clinical responsibility and how is disagreement with the AI handled?
  • What post-deployment monitoring and material update notification does the vendor provide?

Data and contract questions

  • Where are images and derived data processed and retained?
  • Which PACS, RIS, pathology, and EHR integrations are supported in production?
  • Can data be used for model improvement, and what controls govern secondary use?

Evidence and Regulation

FDA Clearances on Record

Odin Vision appears on 3 cleared products in the federal 510(k) record, across 1 device type.

A clearance means the FDA agreed the product is close enough to something already on the market to be sold for that use. It is not a finding that the product helps patients, and it is not a ranking against anything else on this page. A company is linked to an FDA clearance only when the 510(k) applicant name on the government record is confirmed by hand to be that same company, including former corporate names. Name similarity alone is never enough, and rejected matches are listed below with the reason.

What the Published Research Says About This Work

Independent studies on the work itself help separate category evidence from one company's claims.

First-Hand Sources